% | $
Quotes you view appear here for quick access.

Progenics Pharmaceuticals, Inc. Message Board

galaberge 9 posts  |  Last Activity: Nov 15, 2015 7:06 AM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • galaberge galaberge Nov 15, 2015 7:06 AM Flag

    I fully agree with what you say. It's time for HZNP to step out of this mess and go to buy another company. We loose our time...and our money with DEPO

  • Just google the link : " youtubeDOTcom/watch?v=8lFma8g3eSM "

    Long and strong HZNP

    Sentiment: Strong Buy

  • Just go to the website of HZNP and it is very easy and very instructive.

  • BELBUCA™ Approval
    First and only buprenorphine buccal patch for chronic pain
    - Approved for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
    - Combines proven efficacy & established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility
    - Commercial launch expected in Q1 2016
    - Seven dosage strengths, allowing for flexible dosing ranging from 75 μg to 900 μg every 12 hours
    - Enables physicians to individualize titration and treatment based on the optimally effective and tolerable dose for each patient
    - Preparations for launch ongoing
    - Plans to expand our pain sales force and infrastructure
    - Building inventory to support launch

    100M Adults in U.S.
    130M Opioid Rx /yr
    ~$13B Market

    Given the recent approval of BELBUCA™, branded resources will be re-allocated to support launch BELBUCA™ with sales force expansion

    Check the PDF presentation by googling : " Endo International plc Q3 2015 Earnings Report November 5, 2015 " and look at the " Earnings Presentation Q3 2015 "

    Very interesting.

    We could probably see NET revenue in the order of : $ 13 Billions X 20% X 15%(royalties) = $ 400 Millions for BDSI on an annual basis or $8/share per year or which can be translated in a PPS of $80 (assuming a P/E of 10)

    Sentiment: Strong Buy

  • galaberge galaberge Oct 25, 2015 7:44 AM Flag

    Good and interesting find. We will see a real take-off of BDSI in the coming days with the PR of the approval. GLTA

    Sentiment: Strong Buy

  • Reply to

    Tony Plohoros

    by kiddo1428 Sep 23, 2015 12:44 AM
    galaberge galaberge Sep 23, 2015 5:47 AM Flag

    More :

    "Since founding 6 Degrees (formerly Media Mind) in 2007, Plohoros and his team have provided strategic counsel and tactical support to leading and emerging biopharmas, as well as industry service providers, including: Acorda Therapeutics, Chimerix, Endo Pharmaceuticals, GlaxoSmithKline, IMS Health, Johnson & Johnson, Mars, NGM Biopharmaceuticals, NPS Pharmaceuticals, OptumInsight, Pfizer, REGENXBIO, sanofi­‐aventis, Sarepta Therapeutics, UnitedHealth Group, UPenn and others."

  • Reply to

    Tony Plohoros

    by kiddo1428 Sep 23, 2015 12:44 AM
    galaberge galaberge Sep 23, 2015 5:36 AM Flag

    Background of the 6 Degrees firm:


    6 Degrees PR

    March 2010 – Today (5 years-7 monts)

    Thriving in the complex arena of health care requires deep expertise across industry sectors, varied stakeholders and first-rate relationships with top-tier, trade and online media. 6 Degrees has that unique combination, as a results-oriented, full-service public relations firm serving life sciences companies. Our team brings distinctive perspectives as corporate communicators, federal regulators, policy and news media. We move seamlessly between services including corporate and product portfolio positioning, regulatory communications strategy, issues management, media platform, executive positioning, thought-leadership and public affairs. Our insider’s knowledge of how different systems work distinguishes our approach. We come together, for large global, small, private or public sector organizations, with one aim: to deliver tangible, measurable results in the service of our clients’ business goals. "

  • The FDA designates Cempra's Phase 3-stage Taksta (CEM-102) a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections ((ABSSSI)). Taksta (sodium fusidate) is orally active against Gram-positive bacteria including all strains of Staphylococcus aureus.

    QIDP status qualifies Taksta for Fast Track and Priority Review in addition to an additional five-year period of market exclusivity for the indication, if approved.

    Taksta is the second candidate in Cempra's pipeline to be designated a QIDP. The first was solithromycin for the treatment of community acquired bacterial pneumonia.

    The FDA designates Cempra's (NASDAQ:CEMP) Phase 3-stage solithromycin for Fast Track review for the treatment of community acquired bacterial pneumonia (CABP). It has also been tagged a Qualified Infectious Disease Product for the treatment of CABP.The designations provide for a rolling review of the New Drug Application (NDA) and a five-year period of market exclusivity for the indication, if approved.

    Sentiment: Strong Buy

  • Reply to

    Hallmark of True Genius

    by geringerart Aug 29, 2015 1:44 AM
    galaberge galaberge Aug 29, 2015 8:21 AM Flag

    PB-Very good post

7.00+0.01(+0.14%)Nov 27 1:00 PMEST